Company Description
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer.
Its product pipeline includes YSJA, a conventional rabies vaccine, which is in marketed stage; PIKA, a rabies vaccine, which is in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic candidate that is in phase I trial for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine, which is in phase I trial; PIKA YS-HBV-002, an immune-therapy vaccine that is in preclinical trial for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine, which are in preclinical trials.
The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024.
LakeShore Biopharma Co., Ltd was founded in 1994 and is based in Beijing, China.
| Country | China |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 573 |
| CEO | Wang Xu |
Contact Details
Address: Building No. 2, 38 Yongda Road Beijing, 102629 China | |
| Phone | 86 10 8920 2086 |
| Website | lakeshorebio.com |
Stock Details
| Ticker Symbol | LSB |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | CNY |
| CIK Code | 0001946399 |
| ISIN Number | KYG9845F1090 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Wang Xu | Chief Executive Officer and Director |
| Dr. Yuan Liu Ph.D. | Head of Vaccine Research |
| Dr. Hui Shao C.F.A., M.B.A., Ph.D. | President, Chief Business Officer and Vice Chairman |
| Rui Yu M.B.A., M.S. | Chief Financial Officer and Director |
| Zhiyuan Ran | Head of Marketing and Sales |
| Dr. Honggang Teng | Head of Production and Quality Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 31, 2025 | 6-K | Report of foreign issuer |
| Jul 31, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Jul 22, 2025 | SCHEDULE 13D | Filing |
| Jul 15, 2025 | SCHEDULE 13D/A | Filing |
| Jul 15, 2025 | 6-K | Report of foreign issuer |
| Jul 8, 2025 | 6-K | Report of foreign issuer |
| May 12, 2025 | 6-K | Report of foreign issuer |
| May 6, 2025 | 6-K | Report of foreign issuer |
| Mar 25, 2025 | 6-K | Report of foreign issuer |
| Mar 14, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |